FLT3–Menin Combination Therapy for AML Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FLT3 inhibitors face challenges in efficacy as monotherapy and are limited by resistance mechanisms, while menin inhibitors show promise in treating leukemia but require effective combination therapies.
Innovation Solution
A combination therapy comprising FLT3 inhibitors and menin inhibitors, which can be administered separately or together, to target FLT3-related hematological malignancies, including acute myeloid leukemia, by blocking FLT3 activation and modulating chromatin structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If FLT3 inhibitors are used as monotherapy, then the treatment approach is simple, but efficacy is limited and resistance mechanisms develop
Solution Approach 1:
The patent combines FLT3 inhibitors with menin inhibitors into a dual-target therapy regimen. This merging of two different therapeutic mechanisms addresses the limitation of monotherapy by simultaneously targeting FLT3 signaling pathways and menin-mediated chromatin regulation, thereby improving therapeutic efficacy while overcoming resistance mechanisms that develop with single-agent treatment
2Measurement precision
If FLT3 inhibitors are used to target FLT3-mutated AML, then specific therapeutic effect is achieved, but resistance mechanisms limit long-term efficacy
Solution Approach 1:
The patent changes the therapeutic parameter from single-target inhibition to dual-target inhibition. By introducing menin inhibitors alongside FLT3 inhibitors, the therapy modifies the biochemical parameters of cancer cell suppression, creating a more comprehensive blockade that prevents resistance development while maintaining specific targeting of FLT3-mutated AML cells
3Reliability
If combination therapy with FLT3 inhibitors and menin inhibitors is used, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent segments the complex combination therapy into two distinct but complementary components: FLT3 inhibitors and menin inhibitors. This segmentation allows each agent to be optimized for its specific target while being administered as part of a coordinated regimen, managing treatment complexity through structured division of therapeutic functions
Data Source
AI summary
Disclosed herein are combinations comprising an inhibitor of FLT3 and an inhibitor of menin. Also described are combinations of specific irreversible inhibitors of FLT3 and irreversible inhibitors of menin. Also described are methods of using the combinations for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.